CBD Oil Product Recalled Due to High Lead Levels, FDA Announces
Complete the form below and we will email you a PDF version of "CBD Oil Product Recalled Due to High Lead Levels, FDA Announces"
A Florida CBD company is voluntarily recalling a CBD tincture product after a state agency tested a random sample and found dangerous levels of lead.
According to the Florida Department of Agriculture and Consumer Services (FDACS), a sample of a Kore Organic Watermelon CBD oil tincture, produced by Summitt Labs, contained 4.7 parts per million of lead.
The recall was amplified by the Food and Drug Administration (FDA) on Friday, May 15.
When informed of these lead levels by the FDACS, Summitt Labs began an internal investigation and sent off another tincture sample to be tested by an independent lab. This test found lower lead levels (0.5 parts per million), which were within legal state limits.
But, based on the test from the FDACS, the Tampa-based company still initiated a full recall of all Kore Organic Watermelon CBD oils.
Lead exposure can result in significant adverse health effects even in otherwise healthy individuals. According to the World Health Organization, “there is no known level of lead exposure that is considered safe.” The global health authority has linked exposure to the heavy metal with high blood pressure, joint and muscle pain, headaches or abdominal pain, mood disorders, and impairments in memory and concentration in adults.
To this date, Summitt Labs maintains that it has never had a call, complaint, or report of any adverse effect from the use of its Kore CBD oil product.
Nevertheless, the company has notified its distributors and customers by email, phone, and personal visits to ensure the return of the CBD oils in question.
Any consumer that still possesses a Kore Organic Watermelon CBD oil product has been urged to contact Summitt Labs by phone (833 810-5673) or via its website.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product,” the FDA notice reads.
The federal agency has also encouraged any consumers who have experienced adverse reactions to the product to report their symptoms to the FDA’s own MedWatch Adverse Event Reporting program.
CBD isn’t currently recognized as an approved food item or dietary supplement by the FDA. However, the federal agency still regularly issues warning letters to companies selling CBD products that claim to treat medical conditions.